GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug.

The drug was sold at different times by GSK, Pfizer, Sanofi and Boehringer Ingelheim. Ranitidine, which was sold under the Zantac brand name, was pulled off the market in 2020 on concerns it could ...

GSK has stopped (PDF) development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 pneumococcal 24-valent vaccine candidate for adults in favor of a ...

Novartis this morning increased its earnings guidance, saying it anticipates full-year operating profit ... getting attention from pharma, it seems. GSK this morning said it had acquired an ...

Looking ahead, GSK maintains its guidance for the full year of 2024, expecting turnover growth between 7% to 9% and core operating profit growth between 11% to 13%. The company is optimistic about ...

Also Read: Just After Pfizer’s RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population Specialty Medicine sales increased ...

GSK reveals steep fall in vaccine sales, backs outlook 07:13 , Graeme Evans GSK today reported a ...

During a press conference earlier today, GSK officials, alongside Governor Josh Shapiro and Department of Community and Economic Development (DCED) Secretary Rick Siger, announced the investment ...

GSK has also taken the opportunity to throw out some of research products that were not producing results. Development of a PI3kb inhibitor, GSK2636771, has been terminated as part of the R&D rethink.

LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...

GSK Plc acquired an experimental drug from Chinese biotech firm Chimagen Biosciences for as much as $850 million, adding to the British drugmaker’s pipeline of potential treatments for lupus.